Complement Therapeutics Receives UK CTA Approval to Advance CTx001 into Opti-GAIN Phase I/II Clinical Trial in Geographic Atrophy Secondary to AMD – Complement Therapeutics Written by admin on January 29, 2026. Posted in Press Release.

This is fantastic news from Complement Therapeutics! MHRA CTA approval for CTx001, which will lead to an expansion of the clinical trials into both the US and UK. #FDA #MHRA #clinicaltrials #AMD #IND #compelment #ophthalmology